GlassScriptPhysician profile
Roy C Katzin
NPI 1801987748
$4,920.00
in general payments reported to CMS, 2019-2025
39 companies · $37.10 in 2025
The $37.10 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,122 · 2020: $147 · 2021: $367 · 2022: $223 · 2023: $23.61 · 2025: $37.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $60.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $60.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $2,751.88 | 2019 | |
| Emd Serono, INC. | $205.37 | 2019 | |
| Abbott Laboratories | $203.16 | 2019 | |
| Amgen INC. | $175.15 | 2019-2021 | |
| Biogen, INC. | $146.64 | 2019-2022 | |
| Eisai INC. | $125.02 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $103.31 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $94.69 | 2019-2022 | |
| Ucb, INC. | $82.80 | 2019-2022 | |
| Merz North America, INC. | $71.31 | 2019 | |
| Genentech USA, INC. | $65.28 | 2019 | |
| Mdd US Operations, LLC | $63.97 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.55 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $56.77 | 2019-2020 | |
| Integra Lifesciences Corporation | $53.58 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $53.51 | 2019-2021 | |
| Lilly USA, LLC | $50.75 | 2020-2025 | Kisunla, Amyvid |
| Acorda Therapeutics, INC | $49.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $48.22 | 2019 | |
| Alexion Pharmaceuticals, INC. | $40.66 | 2019-2022 | |
| Abbvie INC. | $40.04 | 2021-2023 | |
| Livanova USA, INC. | $32.51 | 2019 | |
| Neurelis, INC. | $31.21 | 2020-2021 | |
| Lundbeck LLC | $30.66 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.40 | 2021 | |
| Sk Life Science, INC. | $25.80 | 2022 | |
| Csl Behring | $23.10 | 2020 | |
| Aprecia Pharmaceuticals, LLC | $21.89 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.67 | 2021 | |
| Aquestive Therapeutics, INC. | $20.95 | 2022 | |
| Allergan, INC. | $19.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.20 | 2021 | |
| Assertio Therapeutics, INC. | $16.73 | 2019 | |
| Neurocrine Biosciences, INC. | $16.67 | 2022 | |
| Grifols USA, LLC | $15.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.66 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Katzin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.